Journal of Clinical Oncology

Addition of chemo-immunotherapy to standard induction chemotherapy for high-risk neuroblastoma.

Journal of Clinical Oncology

Karen S. Fernandez, Amit J. Sabnis, Ruetima Titapiwatanakun, Katherine Baker, Wendy Tcheng

Ulixertinib in patients with tumors with MAPK pathway alterations: Results from NCI-COG Pediatric MATCH trial Arm J (APEC1621J).

Journal of Clinical Oncology

Kieuhoa Tran Vo, Amit J. Sabnis, Paul M. Williams, Sinchita Roy-Chowdhuri, David R. Patton, Brent Coffey, Joel M. Reid, Jin Piao, Lauren Saguilig, Todd Allen Alonzo, Stacey L. Berg, Alok Jaju, Elizabeth Fox, Douglas S. Hawkins, Margaret M. Mooney, Naoko Takebe, James V. Tricoli, Katherine A. Janeway, Nita Seibel, Donald Williams Parsons

Phase 1/2 study of elraglusib (9-ING-41), a small molecule selective glycogen synthase kinase-3 beta (GSK-3ß) inhibitor, alone or with irinotecan, temozolomide/irinotecan or cyclophosphamide/topotecan in pediatric patients with refractory malignancies: I

Journal of Clinical Oncology

Bradley DeNardo, Jennie Foster, Navin R. Pinto, Giselle Linda Saulnier Sholler, Kieuhoa Tran Vo, Ami Vijay Desai, Jessica Sun, Lars M. Wagner, Margaret E Macy, Rajen Mody, Javier E. Oesterheld, Thomas Cash, Roma Bhuta, Eveline Barbieri, Andrew DJ Pearson, Ludimila Cavalcante, Francis J. Giles, Rishi Ramesh Lulla

Clinical and biologic predictors of response to MIBG therapy: A report from the new approaches to neuroblastoma therapy (NANT) consortium.

Journal of Clinical Oncology

Kieuhoa Tran Vo, Katherine K. Matthay, Susan G. Groshen, Yueh-Yun Chi, Meaghan Granger, Julie R. Park, Araz Marachelian, Steven G. DuBois

Clinical impact of molecular tumor profiling in pediatric, adolescent, and young adult patients with extra-cranial solid malignancies: An interim report from the GAIN/iCat2 study.

Journal of Clinical Oncology

Alanna J. Church, Laura Corson, Pei-Chi Kao, Alma Imamovic-Tuco, Wenjun Kang, Navin R. Pinto, Luke Maese, Theodore Willis Laetsch, AeRang Kim, Susan Colace, Margaret E Macy, Mark A. Applebaum, Rochelle Bagatell, Amit J. Sabnis, Daniel Weiser, Julia Lynne Glade Bender, Samuel Louis Volchenboum, Steven G. DuBois, Wendy B. London, Katherine A. Janeway

Phase II trial of olaparib in combination with ceralasertib in patients with recurrent osteosarcoma.

Journal of Clinical Oncology

Suzanne J. Forrest, Michael D. Kinnaman, J Andrew Livingston, Kieuhoa Tran Vo, Priscilla Merriam, Catherine Clinton, Kylene Desmith, Kerri Cavanaugh, Brunella Felicetti, Simon Smith, Emma Dean, Pei-Chi Kao, Wendy B. London, E. Alejandro Sweet-Cordero, Katherine A. Janeway

Updated entrectinib data in children and adolescents with recurrent or refractory solid tumors, including primary CNS tumors.

Journal of Clinical Oncology

Ami Vijay Desai, Giles W. Robinson, Ellen M. Basu, Jennifer Foster, Karen Gauvain, Amit Sabnis, Suzanne Shusterman, Margaret E Macy, Luke Maese, Janet Yoon, Thomas Cash, Mohamed Abdelbaki, Kellie Nazemi, Brian D. Weiss, Saibah Chohan, Alison Cardenas, Katherine Hutchinson, Guillaume Bergthold, Amar J. Gajjar, Elizabeth Fox

Phase I trial of pazopanib in combination with irinotecan and temozolomide (PAZIT) for children and young adults with advanced sarcoma.

Journal of Clinical Oncology

Kieuhoa T. Vo, Jennifer G. Michlitsch, Avanthi T. Shah, Joel M. Reid, Sarah A. Burhow, Eloise M. Graham, Fabienne Hollinger, Matthew A. Zapala, Janel Long-Boyle, Mi-Ok Kim, Katherine K. Matthay, Steven G. DuBois

Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors.

Journal of Clinical Oncology

Giles W. Robinson, Amar J. Gajjar, Karen Marie Gauvain, Ellen M. Basu, Margaret E Macy, Luke Devon Maese, Amit J. Sabnis, Jennifer Haunani Foster, Suzanne Shusterman, Janet Yoon, Brian D. Weiss, Mohamed Abdelbaki, Mufiza Farid-Kapadia, Georgina Meneses-Lorente, Alison Cardenas, Katherine Hutchinson, Guillaume Bergthold, Edna Chow Maneval, Elizabeth Fox, Ami Vijay Desai

Phase 1 study of entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in children, adolescents, and young adults with recurrent or refractory solid tumors.

Journal of Clinical Oncology

Ami Vijay Desai, Garrett M. Brodeur, Jennifer Foster, Stacey L. Berg, Ellen M. Basu, Suzanne Shusterman, Amit J. Sabnis, Margaret Macy, Janet Yoon, Karen Gauvain, Vanessa Esquibel, Edna Chow Maneval, Pratik S. Multani, Elizabeth Fox

Pages